Cargando…

Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung Cancer

Having demonstrated that apolipoprotein A-I (apoA-I) mimetic peptides ameliorate cancer in mouse models, we sought to determine the mechanism for the anti-tumorigenic function of these peptides. CT-26 cells (colon cancer cells that implant and grow into tumors in the lungs) were injected into wild-t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chattopadhyay, Arnab, Yang, Xinying, Mukherjee, Pallavi, Sulaiman, Dawoud, Fogelman, Hannah R., Grijalva, Victor, Dubinett, Steven, Wasler, Tonya C., Paul, Manash K., Salehi-Rad, Ramin, Mack, Julia J., Iruela-Arispe, M. Luisa, Navab, Mohamad, Fogelman, Alan M., Reddy, Srinivasa T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998131/ https://www.ncbi.nlm.nih.gov/pubmed/29899427 http://dx.doi.org/10.1038/s41598-018-26755-0

Ejemplares similares

ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV
por: Daskou, Maria, et al.
Publicado: (2022)

ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer
por: Cedó, Lídia, et al.
Publicado: (2016)

ApoA-I mimetics favorably impact cyclooxygenase 2 and bioactive lipids that may contribute to cardiometabolic syndrome in chronic treated HIV
por: Daskou, M., et al.
Publicado: (2021)

Apolipoprotein A-I Mimetic Peptides Prevent Atherosclerosis Development and Reduce Plaque Inflammation in a Murine Model of Diabetes
por: Morgantini, Cecilia, et al.
Publicado: (2010)

Transgenic tomatoes expressing the 6F peptide and ezetimibe prevent diet-induced increases of IFN-β and cholesterol 25-hydroxylase in jejunum
por: Mukherjee, Pallavi, et al.
Publicado: (2017)

Oxidized phospholipids cause changes in jejunum mucus that induce dysbiosis and systemic inflammation
por: Mukherjee, Pallavi, et al.
Publicado: (2021)

Role of enterocyte Enpp2 and autotaxin in regulating lipopolysaccharide levels, systemic inflammation, and atherosclerosis
por: Chattopadhyay, Arnab, et al.
Publicado: (2023)

Efficacy of tomato concentrates in mouse models of dyslipidemia and cancer
por: Chattopadhyay, Arnab, et al.
Publicado: (2015)

HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
por: Chyu, Kuang-Yuh, et al.
Publicado: (2015)

An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration
por: Chen, Xun, et al.
Publicado: (2009)

Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men
por: Ma, Cheng, et al.
Publicado: (2015)

Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity
por: Yoo, Jeong-Ah, et al.
Publicado: (2015)

SIDT2 Associates with Apolipoprotein A1 (ApoA1) and Facilitates ApoA1 Secretion in Hepatocytes
por: Sampieri, Alicia, et al.
Publicado: (2023)

ApoA-1 in Diabetes: Damaged Goods
por: Ory, Daniel S., et al.
Publicado: (2010)

The ApoA-I mimetic peptide 4F attenuates in vitro replication of SARS-CoV-2, associated apoptosis, oxidative stress and inflammation in epithelial cells
por: Theodoros, Kelesidis, et al.
Publicado: (2021)

ApoA-1 mimetic restores adiponectin expression and insulin sensitivity independent of changes in body weight in female obese mice
por: Marino, J S, et al.
Publicado: (2012)

ApoA-I Mimetic Peptide Reduces Vascular and White Matter Damage After Stroke in Type-2 Diabetic Mice
por: Wang, Xiaohui, et al.
Publicado: (2019)

Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent
por: Lebherz, Corinna, et al.
Publicado: (2007)

FAMP, a Novel ApoA‐I Mimetic Peptide, Suppresses Aortic Plaque Formation Through Promotion of Biological HDL Function in ApoE‐Deficient Mice
por: Uehara, Yoshinari, et al.
Publicado: (2013)

HDL as a Biomarker, Potential Therapeutic Target, and Therapy
por: Navab, Mohamad, et al.
Publicado: (2009)

An apoA-I mimetic peptide facilitates off-loading cholesterol from HDL to liver cells through scavenger receptor BI
por: Song, Xuelei, et al.
Publicado: (2009)

Brain ApoA-I, ApoJ and ApoE Immunodetection in Cerebral Amyloid Angiopathy
por: Camacho, Jessica, et al.
Publicado: (2019)

The unsolved mystery of apoA-I recycling in adipocyte
por: Wang, Shuai, et al.
Publicado: (2016)

NOTCH regulation of the endothelial cell phenotype
por: Mack, Julia J., et al.
Publicado: (2018)

D-4F, an ApoA-I mimetic peptide ameliorating TRPA1-mediated nocifensive behaviour in a model of neurogenic inflammation
por: Oehler, Beatrice, et al.
Publicado: (2020)

Oral Apolipoprotein A‐I Mimetic D‐4F Lowers HDL‐Inflammatory Index in High‐Risk Patients: A First‐in‐Human Multiple‐Dose, Randomized Controlled Trial
por: Dunbar, Richard L., et al.
Publicado: (2017)

LCAT, ApoD, and ApoA1 Expression and Review of Cholesterol Deposition in the Cornea
por: Flores, Rhonda, et al.
Publicado: (2019)

Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study
por: Walldius, Göran, et al.
Publicado: (2021)

Effects of lipid-probe interactions in biochemical fluorometric methods that assess HDL redox activity
por: Kelesidis, Theodoros, et al.
Publicado: (2012)

Autophagy Alteration in ApoA-I Related Systemic Amyloidosis
por: Del Giudice, Rita, et al.
Publicado: (2022)

Effects of Individual Amino Acids on PPARα Transactivation, mTORC1 Activation, ApoA-I Transcription and pro-ApoA-I Secretion
por: Tayyeb, Jehad Z., et al.
Publicado: (2022)

Effect of apoA-I on cholesterol release and apoE secretion in human mature adipocytes
por: Bencharif, Karima, et al.
Publicado: (2010)

Anti-inflammatory and Antioxidant Properties of HDLs Are Impaired in Type 2 Diabetes
por: Morgantini, Cecilia, et al.
Publicado: (2011)

Endothelial NOTCH1 is suppressed by circulating lipids and antagonizes inflammation during atherosclerosis
por: Briot, Anaïs, et al.
Publicado: (2015)

Human apoA-I[Lys107del] mutation affects lipid surface behavior of apoA-I and its ability to form large nascent HDL
por: Gorshkova, Irina N., et al.
Publicado: (2022)

HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL
por: Kelesidis, Theodoros, et al.
Publicado: (2011)

Development of synthetic high-density lipoprotein-based ApoA-I mimetic peptide-loaded docetaxel as a drug delivery nanocarrier for breast cancer chemotherapy
por: Gong, Miaomiao, et al.
Publicado: (2019)

HDL-apoA-I Exchange: Rapid Detection and Association with Atherosclerosis
por: Borja, Mark S., et al.
Publicado: (2013)

Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer
por: Georgila, Konstantina, et al.
Publicado: (2019)

Clinical ApoA‐IV amyloid is associated with fibrillogenic signal sequence
por: Canetti, Diana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_53j5f0grtk6o897rhvhsdkquff